The purpose of this study is to find out if we can improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by combining two drugs for acute lymphoblastic leukemia. In this study you will be given the first study drug (Inotuzumab Ozogamicin) for up to 7 weeks and then a second leukemia drug (Blinatumomab) for up to 31 weeks.
If you choose to take part, you will get the study drug through and IV and this can be given both inpatient and outpatient to monitor your safety. You will have a bone marrow test to determine if you are eligible for the study and you will have bone marrow biopsies and blood samples a few times during the study. You will also receive a physical exam, ECG, height, and weight at the first visit.
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Katarzyna Jamieson
Medicine- Oncology
Clinical or Medical
Interventional
Cancer (Leukemia)
19-0265
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
